Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P930027/S038

IMMULITE 2000 PSA

Siemens Healthcare Diagnostics, Inc. · Decision date Apr 21, 2026

FDA DECISIONP930027/S038

What did the FDA approve?

FDA records P930027/S038 as a supplement to PMA P930027, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Apr 21, 2026.

FDA approval order statement

approval of the instrument manufacturing site change for the IMMULITE 2000XPi analyzer to the Siemens Healthcare Diagnostics instrument manufacturing facility located in Llanberis, Wales
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Immunology
Decision date
Apr 21, 2026
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P930027/S038
Regulatory pathway
PMA supplement
Product code
MTF
Decision code
APPR
Decision date
Apr 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer.

Product code
MTF
FDA device class
3

For the original device and its historical approval scope, see PMA P930027. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P930027 · Original PMA

    IMMULITE SYSTEMS PSA & THIRD GENERATION PSA REAGENTS

  2. P930027/S036 · Related supplement

    IMMULITE 2000 Prostate-Specific Antigen (PSA)

  3. P930027/S038 received

    Application receipt date recorded by FDA.

  4. P930027/S038 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P930027. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P930027

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.PMA approvalSep 15, 1995FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 14, 2025FDA
IMMULITE 2000 PSAP930027/S037
Siemens Healthcare Diagnostics, Inc.PMA supplementOct 30, 2025FDA
IMMULITE 2000 PSAP930027/S039
Siemens Healthcare Diagnostics, Inc.PMA supplementJul 27, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 20, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementSep 22, 2026FDA

Explore the linked device profile

Other records with product code MTF

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 26, 2026FDA
Roche Diagnostics Corp.PMA supplementApr 29, 2026FDA
Roche Diagnostics Corp.PMA supplementFeb 27, 2026FDA
ABBOTT LABORATORIESPMA supplementFeb 23, 2026FDA
ABBOTT LABORATORIESPMA supplementFeb 12, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Healthcare Diagnostics, Inc.

Headquarters
Not reported
FDA applicant address
Glyn Rhonwy, Llanberis, Gwynedd Ll55 4el, LL554EL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records